About the Company
We do not have any company description for Metagenomi, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Metagenomi, Inc.
Metagenomi Appoints Laurence Reid, PhD to its Board of Directors
Dr. Reid brings 30 years of experience in building biotech companies based on innovative scientific platforms and shaping ...
Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results
Presented three abstracts at American Society of Gene & Cell Therapy (“ASGCT”) demonstrating early proof-of-concept data ...
Analysts Have Been Trimming Their Metagenomi, Inc. (NASDAQ:MGX) Price Target After Its Latest Report
Metagenomi, Inc. (NASDAQ:MGX) just released its latest quarterly results and things are looking bullish. The results overall were credible, with revenues of US$8.5m beating expectations by 10%.
Metagenomi Reports Strong Q2 2025 Financial Results
Metagenomi, Inc. ( ($MGX) ) has shared an announcement. Metagenomi, Inc. reported its second quarter 2025 financial results and business updates, ...
Metagenomi Announces New Appointment to its Board of Directors
EMERYVILLE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its ...
Metagenomi (MGX) Presents Latest in Gene Editing Technologies
Metagenomi, Inc. (NASDAQ:MGX) is one of the 11 Best New Penny Stocks to Buy Right Now. On May 14, Metagenomi, Inc. (NASDAQ:MGX) announced that it is presenting three abstracts at the American Society ...
Metagenomi: Q2 Earnings Snapshot
Metagenomi Inc. (MGX) on Tuesday reported a loss of $19.9 million in its second quarter.
Metagenomi, Inc. Welcomes Eric Bjerkholt to Board of Directors
Metagenomi, Inc., a precision genetic medicines company, announced that Eric Bjerkholt, CFO of Mirum Pharmaceuticals, will join its Board of Directors effective January 27, 2025.
Metagenomi, Inc. (MGX) Gets a Buy from TD Cowen
TD Cowen analyst Joseph Thome maintained a Buy rating on Metagenomi, Inc. today. The company’s shares closed today at $1.88. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing ...
Metagenomi, Inc. CEO Brian C. Thomas to Present at 43rd Annual J.P ...
Metagenomi, Inc., a company focused on precision genetic medicines, announced that its CEO and founder, Brian C. Thomas, PhD, will present at the 43rd Annual J.P. Morgan Healthcare Conference on ...
Metagenomi: Q1 Earnings Snapshot - WTOP News
EMERYVILLE, Calif. (AP) — EMERYVILLE, Calif. (AP) — Metagenomi Inc. (MGX) on Tuesday reported a loss of $25 million in its first quarter. On a per-share basis, the Emeryville… ...
Shareholders of Metagenomi, Inc. Should Contact The Gross Law Firm ...
Shareholders of Metagenomi, Inc. Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your Rights – MGX Provided by GlobeNewswire Nov 20, 2024 5:41pm ...
Similar Companies
Loading the latest forecasts...